. @crescolabs CEO: Rescheduling Ushers in a New Era of Medical Cannabis Patient Care –
Medical cannabis rescheduling regulatory impact is poised to transform research and patient care. This shift could enable more rigorous clinical trials and standardized treatment protocols. Patients and clinicians should stay informed about evolving…
Starting Federally-Backed Cannabis Clinical Trials in the USA
The opening of federally-backed cannabis clinical trials marks a pivotal moment for evidence-based cannabis medicine. This new infrastructure enables rigorous research previously hindered by federal restrictions. Clinicians should monitor these…
Cannabinoid Clinical Trials: Anxiety & Tourette Syndrome
Cannabinoid clinical trials anxiety disorders reveal modest evidence for CBD in reducing acute anxiety symptoms. THC-dominant formulations may increase anxiety and are not recommended. More rigorous trials are needed to establish cannabinoids as…
Federal Government Reclassifying Medical Marijuana – YouTube Insights
The federal government reclassifying medical marijuana from Schedule I to Schedule II marks a pivotal change. This shift enables controlled clinical trials previously hindered by regulations. It opens new avenues for research and evidence-based medical…
Clinical Trials of CBD for Anxiety and Tourette
CBD anxiety clinical trials demonstrate promising efficacy for generalized and social anxiety disorders with good safety. THC formulations show mixed results and possible anxiety worsening at high doses. Current evidence supports CBD as an adjunctive…
Duquesne University, Terra Pharm Partner for Cannabis Research
The Duquesne University cannabis research partnership with Terra Pharm marks a significant step in advancing clinical cannabis studies. This collaboration highlights the importance of academic-industry partnerships in generating rigorous evidence. Such…
Feds Ease Cannabis Restrictions and Expand Research Options
Federal cannabis research policy changes are easing restrictions and opening new options for researchers. These changes could accelerate high-quality clinical evidence generation. Practitioners may soon benefit from more robust data to guide therapeutic…
Federal Reclassification of Medical Marijuana Opens New Research Doors for Colorado Scientists
Federal rescheduling medical marijuana from Schedule I to Schedule III removes significant regulatory barriers. This change enables researchers to conduct controlled studies needed for evidence-based treatment. The new classification opens doors for…
Trump Reclassifies Marijuana as Less Dangerous in Major Policy Shift – Healthline
The Trump marijuana policy shift marks a significant federal reclassification of cannabis, reducing its danger status. This change could enable expanded medical marijuana research and standardized clinical trials. Patients and clinicians may soon benefit…
DOJ Moves to Ease Medical Marijuana Restrictions – NBC News
The DOJ medical marijuana rescheduling update signals a significant easing of federal restrictions. This change could enable more clinical research and improve patient access. It marks a pivotal shift in cannabis policy and medical practice.